GleamWall
中文EN

VANI Vivani Medical, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1266806 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-3.9%
TTM EPS YoY26.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-372.2%
ROA-89.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue—————$0$0$0
R&D expense$5.02M$4.46M$4.39M$4.63M$4.52M$4.76M$4.22M$4.30M
SG&A expense$2.51M$2.42M$2.43M$2.18M$2.21M$2.70M$2.34M$2.16M
Operating income-$7.53M-$6.87M-$6.82M-$6.81M-$6.72M-$7.46M-$6.56M-$6.46M
Net income-$7.25M-$6.37M-$6.78M-$6.63M-$6.53M-$7.14M-$6.30M-$6.05M
EBITDA-$7.40M-$6.75M-$6.69M-$6.69M-$6.62M-$7.36M-$6.46M-$6.37M
EPS (basic)-0.08-0.07-0.08—-0.11-0.12-0.11—
EPS (diluted)-0.08-0.07-0.08—-0.11-0.12-0.11—
Weighted avg. shares (diluted)90.12M87.09M81.27M—59.71M59.24M59.24M—
Balance sheet
Cash & equivalents$14.59M$19.89M$19.75M$16.23M$2.63M$6.79M$13.01M$18.35M
Receivables——$12,000—————
Current assets$15.83M$21.64M$21.55M$17.90M$4.17M$8.71M$14.85M$20.44M
PP&E, net$2.76M$2.85M$2.75M$2.88M$2.73M$1.58M$1.61M$1.69M
Total assets$35.31M$41.64M$42.35M$39.39M$25.05M$28.91M$35.45M$41.56M
Current liabilities$6.58M$6.66M$6.78M$6.60M$6.83M$6.72M$6.20M$5.99M
Total liabilities$22.09M$22.67M$23.27M$23.66M$23.74M$24.00M$23.83M$23.95M
Shareholders' equity$13.22M$18.97M$19.09M$15.73M$1.31M$4.91M$11.62M$17.61M
Shares outstanding76.43M89,41084.65M76.43M61.51M59.24M59.24M59.23M
Cash flow statement
Operating cash flow-$6.39M-$6.04M-$6.20M-$6.72M-$6.35M-$6.09M-$5.16M-$5.81M
Capital expenditure$0$99,000$3,000$274,000$823,000$71,000$5,000$296,000
Free cash flow-$6.39M-$6.13M-$6.20M-$6.99M-$7.17M-$6.16M-$5.17M-$6.11M
Investing cash flow$0-$99,000-$3,000-$274,000-$823,000-$71,000-$5,000-$296,000
Financing cash flow$1.09M$5.83M$9.71M$20.59M$2.95M-$95,000-$170,000$4.83M
Depreciation & amortization$129,000$128,000$130,000$117,000$105,000$100,000$102,000$89,000
Stock-based compensation$378,000$313,000$312,000$467,000$276,000$391,000$350,000$402,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.